Generian is a biopharmaceutical company that is revolutionizing drug discovery by focusing on small molecule therapeutics. Their goal is to address the limitations of biologics and enhance the patient experience by increasing convenience and accessibility. They believe that small molecule therapeutics are more economically sustainable and offer greater flexibility in titrating treatments compared to antibodies.

Generian has developed a unique and versatile drug discovery approach that allows them to screen proteins of interest in their native cellular environment. This enables them to discover small molecules that target previously challenging protein targets. By rapidly identifying target binders, Generian can progress candidates with greater mechanistic certainty and efficiency through highly translational phenotypic screening.

Their pipeline includes first-in-class drug candidates that modulate target protein structure and dynamics, resulting in functional inhibition or activation. They have programs for both clinically validated targets and novel targets through their collaboration agreement with Astellas. Generian is dedicated to developing innovative small molecule therapeutics that have the potential to improve patient outcomes and transform the treatment landscape